26 completed, 9 terminated, 5 recruiting, 3 not yet recruiting. 48 Phase 2, 6 Phase 3, 5 Phase 1.
Follow Hemangioma: new trials by email Literature Review of Hemangioma trials Research Report on Hemangioma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Rapamycin Dose-Ranging Efficacy Study in Port Wine Stains Rapamycin cream, Pulsed dyed laser - Port Wine Stains | Phase 2 | Not yet recruiting | AFT Pharmaceuticals, Ltd. | 30 | 2026-11-13 | 2026-10-27 |
| A Phase 2 Study of Sirolimus for Injection (Albumin-bound) in Patients With Progressive or Symptomatic Epithelioid Hemangioendothelioma Sirolimus for injection (Albumin-bound) - Epithelioid Hemangioendothelioma | Phase 2 | Not yet recruiting | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 40 | 2026-08-01 | 2026-07-06 |
| Low- vs High-Dose Sirolimus With Prednisolone for KHE and KMP Sirolimus (RAPAMUNE) - Kaposiform Hemangioendothelioma (KHE), Kasabach Merritt Phenomenon | Phase 2 / Phase 3 | Recruiting | Yi Ji | 76 | 2026-06-16 | 2026-06-18 |
| A Study to Evaluate the Efficacy and Safety of Everolimus in Patients With Teratment-refractory Vascular Anomalies Everolimus - Vascular Malformations, Arteriovenous Malformations | Phase 2 | Not yet recruiting | Yonsei University | 67 | 2026-04-01 | 2026-03-17 |
| SARC046: A Phase II Trial of Nab-Sirolimus in Patients With Progressing or Symptomatic Epithelioid Hemangioendothelioma nab-Sirolimus - Epithelioid Hemangioendothelioma (EHE) | Phase 2 | Recruiting | Sarcoma Alliance for Research through Collaboration | 41 | 2026-02-24 | 2026-05-26 |
| Efficacy and Safety of Different Initial Doses of Oral Propranolol in the Treatment of Ulcerated Infantile Hemangioma propranolol - Infantile Hemangioma | Phase 2 / Phase 3 | Recruiting | West China Hospital | 32 | 2025-01-01 | 2026-11-12 |
| Agnostic Therapy in Rare Solid Tumors Nivolumab - Urachal Cancer, Parathyroid Carcinoma | Phase 2 | Active not recruiting | Instituto do Cancer do Estado de São Paulo | 28 | 2024-07-16 | 2026-10-13 |
| NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) Surgical resection, Proton beam radiation therapy, Pazopanib - Adipocytic Neoplasm, Liposarcoma | Phase 1 / Phase 2 | Recruiting | St. Jude Children's Research Hospital | 139 | 2024-03-27 | 2026-08-03 |
| Real-World Effectiveness and Pharmacogenetics of Belzutifan in VHL Syndrome: The BELIEVE-VHL Trial Belzutifan - Von Hippel Lindau, Von Hippel Lindau Disease | Phase 2 | Recruiting | José Claudio Casali da Rocha | 100 | 2024-01-01 | 2025-09-11 |
| Safety and Tolerability Study of QLS-101 in Adolescents With Sturge-Weber Syndrome (SWS)-Related Glaucoma Due to Elevated Episcleral Venous Pressure (EVP) QLS-101 ophthalmic solution, 2.0 % - Sturge-Weber Syndrome, Glaucoma | Phase 2 | Completed | Qlaris Bio, Inc. | 2 | 2022-11-23 | 2025-01-20 |
| Different Doses of Sirolimus for the Maintenance Treatment of Kaposiform Hemangioendothelioma Sirolimus - Hemangioendothelioma | Phase 2 | Unknown | West China Hospital | 30 | 2022-04-05 | 2024-01-24 |
| The Symptomatic Cerebral Cavernous Malformation Trial of REC-994 REC-994, Placebo - Cerebral Cavernous Malformation | Phase 2 | Completed | Recursion Pharmaceuticals Inc. | 62 | 2022-03-17 | 2026-10-22 |
| A Study to Determine the Safety and Tolerability of 2 Concentrations of QLS-101 QLS-101ophthalmic solution 1%, QLS-101ophthalmic solution 2% - Sturge-Weber Syndrome (SWS), Glaucoma | Phase 2 | Completed | Qlaris Bio, Inc. | 3 | 2021-10-19 | 2025-01-20 |
| ''Efficacy of Propranolol in the Treatment of Infantile Hemangioma" Propranolol Therapy for Infantile Hemangioma - Infantile Hemangioma | Phase 2 | Unknown | Assiut University | 100 | 2021-01-01 | 2020-12-24 |
| Timolol Maleate Gel for the Treatment of Infantile Hemangioma Timolol Maleate Gel+Placebo, Timolol Maleate Gel, Placebo - Infantile Hemangioma | Phase 2 / Phase 3 | Completed | Auson Pharmaceuticals Inc. | 168 | 2020-10-28 | 2024-11-07 |
| Novel Cognitive Treatment Targets for Epidiolex in Sturge- Weber Syndrome Cannabidiol - Sturge-Weber Syndrome | Phase 2 | Completed | Anne Comi, MD | 11 | 2019-10-14 | 2023-05-25 |
| Atorvastatin Treatment of Cavernous Angiomas With Symptomatic Hemorrhage Exploratory Proof of Concept (AT CASH EPOC) Trial Atorvastatin, Placebo - Cerebral Cavernous Malformation | Phase 1 / Phase 2 | Completed | University of Chicago | 80 | 2018-07-17 | 2025-08-22 |
| Treat_CCM: Propranolol in Familial Cerebral Cavernous Malformation Propranolol - Cerebral Cavernous Malformation | Phase 2 | Completed | Mario Negri Institute for Pharmacological Research | 71 | 2018-04-11 | 2022-02-25 |
| Effect of Oral Propranolol on mRNA Expresssion in Symptomatic Cavernous Malformation Propranolol, DNA and RNA Analysis - Cerebral Cavernous Malformations | Phase 2 | Terminated | St. Joseph's Hospital and Medical Center, Phoenix | 4 | 2018-01-24 | 2024-04-19 |
| Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE) Eribulin - Angiosarcoma, Epithelioid Hemangioendothelioma | Phase 2 | Completed | Massachusetts General Hospital | 13 | 2018-01-18 | 2026-08-28 |
Showing 20 of 48. Sign in to see all of them.
Hemangioma, Capillary (12) · Hemangioendothelioma, Epithelioid (9) · Hemangiosarcoma (7) · Hemangioblastoma (6) · Leiomyosarcoma (6) · Sturge-Weber Syndrome (6) · Osteosarcoma (5) · Sarcoma (5) · Sarcoma, Synovial (5) · Chondrosarcoma, Extraskeletal Myxoid (4) · Fibrosarcoma (4) · Hemangioendothelioma (4) · Hemangioma, Cavernous, Central Nervous System (4) · Histiocytoma, Malignant Fibrous (4)
Neoplasms by Histologic Type (48) · Neoplasms, Vascular Tissue (48) · Neoplasms (46) · Nervous System Diseases (20) · Cardiovascular Diseases (19) · Vascular Diseases (17) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (15) · Congenital Abnormalities (14) · Neurocutaneous Syndromes (11) · Angiomatosis (10) · Brain Diseases (8) · Central Nervous System Diseases (8) · Hemangioendothelioma (8) · Hematologic Diseases (8)
Propranolol (7) · Sirolimus (6) · Prednisolone (3) · Sunitinib (3) · Timolol (3) · Adrenal Cortex Hormones (2) · Cannabidiol (2) · Doxorubicin (2) · Everolimus (2) · Ifosfamide (2) · Imiquimod (2) · Nivolumab (2) · Prednisone (2) · Solutions (2) · Vincristine (2)
Anne Comi, MD (3) · M.D. Anderson Cancer Center (3) · West China Hospital (3) · National Cancer Institute (NCI) (2) · Pierre Fabre Dermatology (2) · Qlaris Bio, Inc. (2) · AFT Pharmaceuticals, Ltd. (1) · Assiut University (1) · Auson Pharmaceuticals Inc. (1) · Baylor College of Medicine (1) · Boston Children's Hospital (1) · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (1) · Children's Hospital of Philadelphia (1) · Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau (1) · Grupo Espanol de Investigacion en Sarcomas (1)
United States (30) · China (6) · Spain (5) · Brazil (3) · Canada (3) · France (3) · Italy (3) · Poland (2) · Australia (1) · Czechia (1) · Egypt (1) · Germany (1) · Hungary (1) · Lithuania (1) · Mexico (1)
Anne M Comi, MD (2) · Eric Jonasch, MD (2) · Yi Ji, MD, PhD (2) · Alba Rubio (1) · Albert C. Yan, MD (1) · Angus A Wilfong, MD (1) · Anne M Comi, M.D. (1) · Antonio Casado (1) · B. Wirostko, M.D. (1) · Beth Drolet, MD (1) · Camila MV Moniz, Doctor (1) · Catherine McCuaig, M.D. (1)
PMID 35030255, PMID 22871490, PMID 28486787, PMID 31401903, PMID 31489702, PMID 32014025, PMID 33580918, PMID 19419474, PMID 22105611, PMID 23301692, PMID 24347141, PMID 24526257, PMID 25693013, PMID 26813215, PMID 29571951, PMID 32398113, PMID 33203665, PMID 34082006, PMID 34273457, PMID 34783716, PMID 35443056, PMID 35934010, PMID 36403580, PMID 3691614, PMID 38419711, PMID 39356980, PMID 3936944, PMID 39831682, PMID 40107509, PMID 40120614, PMID 40570636, PMID 41117517, PMID 41608890, PMID 41831614, PMID 41836677
2008 (1), 2017 (1), 2025 (1), N01CM62206 (1), P30CA008748 (1), P30CA046592 (1), U01CA069856 (1), U54NS065705 (1)